List Biotherapeutics, Inc. announced that it expects to receive KRW 21.251203664 billion in funding from SV Investment Corporation, Paratus Investment Inc., Samsung Securities Co., Ltd.

List Biotherapeutics, Inc. announced a private placement to issue 5,800,001 type stocks at a price of KRW 3,664 for gross proceeds of KRW 21,252,363,664 on March 23, 2022. The capital will be raised through 3rd party allocation increase method. The transaction will include participation from SV Scale-up Fund, a fund managed by SV Investment Corporation for 1,666,667 shares, Paratus Innovative Growth M&A PEF, a fund managed by Paratus Investment Inc. for 1,000,000 shares, Paratus Newnormal TCB PEF, a fund managed by Paratus Investment Inc. for 1,333,334 shares, SUFIAION Genome CDMO Investment Fund for 733,334 shares, Samsung Securities Co., Ltd. for 666,666 shares and KD TYEL Investment Fund 1 for 400,000 shares.

The transaction will be completed in two tranches, the first tranche will consist of KRW 9,779,201,222.4 having payment date of March 24, 2022 and second tranche will consist of KRW 11,481,162,442.8 having payment date of April 11, 2022. The transaction has been approved by the board of directors.